Eli Lilly and Company (LLY) is identified as a must-own stock in the biotech sector. Despite trading at a premium over $1,000 per share, the company dominates the obesity and diabetes drug markets, where demand currently exceeds supply. This strong fundamental position in key medical trends of the decade suggests continued growth potential.